Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before and after transplant may stop this from happening.

PURPOSE: This clinical trial is studying the side effects and how well donor stem cell transplant works when given after conditioning therapy in treating patients with hematologic cancer, recurrent or metastatic solid tumor, or other disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Antilymphocyte Serum; Busulfan; Cyclosporine; Cyclosporins; Fludarabine; Fludarabine phosphate; Methotrexate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• High-risk acute leukemia, including any of the following:

• Refractory acute leukemia

• Acute leukemia beyond first remission

• Acute leukemia in first remission with poor prognostic features (e.g., chromosomal changes suggesting poor prognosis)

• Chronic myelogenous leukemia in second chronic, accelerated, or blastic phase

• Severe aplastic anemia that is not responsive to immunosuppressive therapy

• Myelodysplastic syndromes, including any of the following:

• Refractory anemia (RA) or RA with ringed sideroblasts with severe cytopenia

• RA with excess blasts (RAEB)

• RAEB in transformation

• Chronic myelomonocytic leukemia

• Refractory or relapsed non-Hodgkin or Hodgkin lymphoma

• Multiple myeloma

• Biopsy proven measurable solid tumor meeting 1 of the following criteria:

• Recurrent disease after primary treatment and deemed incurable to standard treatment

• Metastatic disease for which no known standard therapy that is potentially curative or definitely capable of extending life expectancy exists

• Must have a related HLA-haploidentical mismatched (3/6 or fewer loci) donor available

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%

• Bilirubin < 2.0 mg/dL

• AST < 3 times upper limit of normal

• Creatinine < 2.0 mg/dL

• Ejection fraction > 40% by MUGA

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics